Last reviewed · How we verify
RVU120
At a glance
| Generic name | RVU120 |
|---|---|
| Also known as | SEL120 |
| Sponsor | Ryvu Therapeutics SA |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- RVU120 Rollover Study (PHASE2)
- RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis (PHASE2)
- RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms (PHASE2)
- Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML (PHASE2)
- Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML (PHASE2)
- RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors (PHASE1, PHASE2)
- RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RVU120 CI brief — competitive landscape report
- RVU120 updates RSS · CI watch RSS
- Ryvu Therapeutics SA portfolio CI